Coenzyme Q10
Of 3,254 on-market coenzyme q10 products in the January 2026 DSLD dump, the median declared dose is 60 mg, and 97.6% list Ubiquinone (oxidized form) as the primary form.
Form share
Of 3,247 products with an identifiable primary form, here is the share held by each form of Coenzyme Q10 on the market today.
Embed this chart
Free to embed on your site or article — attribution and a link back are built into the frame.
| Form | Quality tier | n | Share |
|---|---|---|---|
| Ubiquinone (oxidized form) | Tier 2 | 3,170 | 97.6% |
| Ubiquinol (reduced/active form) | Tier 1 | 77 | 2.4% |
Form share over time
Entry-year breakdown of the top forms, 2012–2025.
Dose distribution
Deciles of declared dose per serving (mg), among 2,754 products with a disclosed amount.
Embed this chart
Free to embed on your site or article — attribution and a link back are built into the frame.
- 46.7% of products fall below the fairy-dust threshold (60 mg, 20% of the studied low dose).
- 12.8% of products don't disclose an amount because Coenzyme Q10 is declared inside a proprietary blend.
Where does your dose rank?
Enter a per-serving dose (mg) to see exactly how it compares to the 2,754 on-market coenzyme q10 products with a disclosed amount. The chart above groups doses into deciles; this looks up the exact percentile for one number.
By dosage form
By target group
Top brands
Search interest over time
How often people search for coenzyme q10 on Google, US only, the last 5 years. This is public interest, not DSLD label data — a spike here doesn't necessarily line up with anything on this page, and Google's own index (100 = that term's peak popularity in the chosen window) is relative, not an absolute search-volume count.
Or see this search directly on trends.google.com.
Forms explained
Standard/most common commercial form but achieved lower plasma CoQ10 than ubiquinol at an equal dose in one small comparison (n=12).
Source: Langsjoen PH, Langsjoen AM. 2014, Clin Pharmacol Drug Dev 3(1):13-17, PMID 27128225
Achieved ~1.7x higher plasma CoQ10 than ubiquinone at an equal 200mg/day dose in direct comparison (n=12).
Source: Langsjoen PH, Langsjoen AM. 2014, PMID 27128225
Reference values
- RDA (adult): not established — Endogenously synthesized; not classified as an essential nutrient. No NIH ODS fact sheet, RDA, or AI exists.
- Tolerable Upper Intake Level (adult): not established — Not established as a formal UL. Hidaka T et al. safety review (PMID 19096117) found no significant adverse effects up to 1200mg/day across trials (typical trial doses 100-200mg/day); a 52-week rat NOAEL of 1200mg/kg/day yields a calculated ADI of ~720mg/day for a 60kg adult. Higher doses have been tested short-term in neurodegenerative-disease trials, but no specific trial is cited here -- not the same as a population UL.
- Studied clinical dose range: 300–300 mg
- Both cited trials used 300mg/day (100mg three times daily; 100mg is the per-dose amount, not a separately tested daily dose), so low and high are both 300. Mortensen SA et al. 2014 (Q-SYMBIO trial), JACC Heart Fail 2(6):641-649, PMID 25282031 -- 100mg TID (300mg/day) x2yr in moderate-severe heart failure: primary endpoint (major adverse cardiovascular events) 15% vs 26% (HR 0.50, P=.003); secondary endpoints all-cause mortality 10% vs 18% (P=.018) and cardiovascular mortality 9% vs 16% (P=.026). Also Sandor PS et al. 2005, Neurology 64(4):713-5, PMID 15728298 -- 300mg/day significantly reduced migraine frequency vs placebo.